Chief MentorLife Sciences

Arthur Klausner is CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance kidney-targeting nanoparticle technology developed at Memorial Sloan Kettering Cancer Center for the treatment of acute kidney injury and polycystic kidney disease.
He currently also serves as boardmember of Monopar Therapeutics, Cennerv Pharma, and Gem Pharmaceuticals. Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures.